GC 1102

Drug Profile

GC 1102

Alternative Names: GC-1102; HepaBig Gene - GC Pharma; Recombinant Hepatitis B Human Immunoglobulin - GC Pharma

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Antivirals; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Viral antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 17 Jan 2018 Green Cross plans a phase II/III trial for Hepatitis B (Prevention) in early 2018
  • 12 Oct 2017 Green Cross Corporation completes a phase I trial for chronic Hepatitis B in South Korea (IV) (NCT02569372)
  • 03 Mar 2017 Phase-II development is ongoing in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top